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Surface tensionPulmonary surfactant is an essential lipid–protein complex to maintain an operative respiratory surface at the
mammalian lungs. It reduces surface tension at the alveolar air–liquid interface to stabilise the lungs
against physical forces operating along the compression–expansion breathing cycles. At the same time, surfac-
tant integrates elements establishing a primary barrier against the entry of pathogens. Lack or deﬁciencies of
the surfactant system are associatedwith respiratory pathologies, which treatment often includes supplementa-
tion with exogenousmaterials. The present review summarises current models on themolecularmechanisms of
surfactant function,with particular emphasis in its biophysical properties to stabilise the lungs and themolecular
alterations connecting impaired surfactant with diseased organs. It also provides a perspective on the current
surfactant-based strategies to treat respiratory pathologies. This article is part of a Special Issue entitled: Mem-
brane Structure and Function: Relevance in the Cell's Physiology, Pathology and Therapy.
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The presence of a pulmonary surfactant was directly linked with re-
spiratory failure by Richard Pattle in England and John Clemens in the
USA while studying the effects of nerve gases in the lungs [1]. A few
years later, Mary Ellen Avery demonstrated that hyalinemembrane dis-
ease (later known as respiratory distress syndrome, RDS) in new-borns
that died after birthwas caused by a lack of surfactant [2]. Consequently,
hyaline membrane disease was associated with the absence of
a surface-active material; under normal conditions, this material pro-
duces a surface tension of around8 dyn/cm. In babies suffering fromhy-
aline membrane disease, the surface tension exceeded 30 dyn/cm. The
ﬁrst successful animal experiments with natural surfactants were per-
formed by Enhorning and Robertson in Stockholm, demonstrating im-
proved survival in preterm rabbits [3,4]. Later, Adams and Fujiwara in
theUSA showed the same beneﬁcial effects of natural surfactants in pre-
term lambs [5,6]. Once the connection between the surfactant and lung
diseases in neonates was established [7–9], exogenous surfactant ther-
apieswere developed. Surfactant replacement therapy (SRT) is current-
ly used as a prophylactic treatment in neonates of less than 35 weeks in
gestational age, decreasing themortality of premature babies up to 80%.
SRT today currently enables premature babies to breathe and survive at
only 25 weeks of gestational age [10].Moreover, surfactant researchhas
been growing and expanding to cover other lung pathologies. The pri-
mary objective of surfactant research is to understand the molecular
and physical mechanisms associated with surfactant function as well
as the processes interfering with the surfactant's activity and contribu-
tion to lung diseases. A better understanding of the primary or second-
ary implications of surfactants in respiratory pathologies is also required
to facilitate the development of successful treatments and efﬁcient clin-
ical surfactant preparations.
1.1. Surfactant composition and structure
Pulmonary surfactant is produced in the lungs and is essential dur-
ing breathing. Because it is placed at the air–liquid alveolar interface,
pulmonary surfactant reduces the surface tension of the thin layer of
water that covers the lung epithelium. A low surface tension reduces
the work of breathing and prevents alveolar collapse. Moreover, surfac-
tant is the ﬁrst barrier that pathogens encounter within one of the larg-
est exposed surfaces of the human body [11–13]. The lung surface area
has been calculated as approximately 100 m2 and facilitates essential
gas exchange activity. For this reason, respiratory pathologies causeFig. 1.Composition of lung surfactant. Proportions of the different lipid and protein components
surfactant mass.13.6% of the deathsworldwide, according to theWorldHealthOrganisa-
tion (2008).
Pulmonary surfactant is a complex mixture of lipids and proteins,
and lipids account for more than 90% of the surfactant by mass (see
Fig. 1). The qualitative and quantitative compositions of the lipids in
the surfactant vary between species and according to environmental
conditions, such as body temperature [14]. Surfactant also changes ac-
cording to physiological constraints, such as the breathing rate or hiber-
nation [15], or due to pathological situations, particularly lung injury
[16,17]. However, the protein composition is also critical for normal sur-
factant function. Surfactant proteins A (SP-A) and D (SP-D) belong to
the collectin protein family. They are directly related to the innate
host defence of the lung and recognise, bind and eliminate pathogens
[18–20]. Surfactant proteins B (SP-B) and C (SP-C) are small hydropho-
bic proteins that are deeply embedded into the surfactant phospho-
lipids; they enhance interfacial adsorption of surface active molecules
into the air–liquid interface and contribute to mechanical stability
of the interfacial ﬁlms [21]. Animal models show that deﬁciencies
in surfactant proteins lead to respiratory pathologies, demonstrating
a direct relationship between surfactant activity and normal lung
performance. Deﬁciencies in SP-A and SP-D are not critical at ﬁrst, al-
though animal models deﬁcient in SP-A develop lung infections more
frequently [22]. SP-D deﬁciency might be related to emphysema [23]
and chronic obstructive pulmonary disease (COPD) [24]. On the other
hand, SP-C deﬁciency is associated with chronic respiratory pathologies
[25], and complete SP-B deﬁciency results in death shortly after birth
[26,27].
1.1.1. Surfactant lipids
Phospholipids are amphipathicmolecules that have apolar andhydro-
philic moiety and non-polar or hydrophobic chains. This type of molecule
adopts a particular arrangement at the air–liquid interface,minimising the
contact between the hydrophobic region and water molecules. Phospho-
lipids thus adopt an energetically favourable orientation, pointing the
polar heads toward the water phase, while the non-polar chains are ori-
ented toward the air.
As shown in Fig. 1, the most abundant component in surfactant is
dipalmitoylphosphatidylcholine (DPPC), representing approximately
40% of the total surfactant mass. DPPC is essential for producing the
very low surface tension observed during compression; its saturated
acyl chains can adopt a highly lateral packed state. Surfactant contains
other saturated phosphatidylcholines (PC), such as palmitoylmirystoyl-
PC (PMPC, 16:0/14:0), and unsaturated PCs, such as palmitoyloleoyl-PCin pulmonary surfactant, represented as occupying proportional areaswith respect to total
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Other functionally important phospholipids in surfactant include a pro-
portion (10–15%) of hydroxylated anionic phospholipids, such as
phosphatidylglycerol (PG) and phosphatidylinositol (PI); these species
are thought to participate in selective interactions with the cationic hy-
drophobic proteins [28–31]. Other phospholipids, such as phosphatidyl-
ethanolamine (PE) and sphingomyelin (SM), appear as minor
components of surfactant and most likely come from other cell mem-
branes. In addition, little amounts of lysophosphatidylcholine (LPC) can
be found [32–34].
As important as the phospholipid composition is, the presence of an
appropriate proportion of cholesterol in surfactant may also be key.
Under normal physiological conditions, cholesterol content is approxi-
mately 3–8% by mass. The other neutral lipids present in small quanti-
ties include cholesterol esters, triglycerides, diglycerides and free fatty
acids [35].
Different surfactant phospholipids offer different structural features
with potentially important functional relevance. The negative charge at
the head groups of anionic species, for example, permits to establish in-
teractions with the positive charges in SP-B and/or SP-C or to interact
with cations such as Ca2+, which might be important for surfactant or-
ganisation. Hydroxylated phospholipids might offer unique possibilities
for H-bonding among lipids or between lipids and proteins. On the
other hand, the hydrophobic segments of phospholipids are deﬁned
by the different fatty acids that esterify the glycerol backbone, differing
in length and the number/position of the double bonds (unsaturation).
Palmitic acid (16:0) is particularly abundant in surfactant phospho-
lipids, speciﬁcally in disaturated species, such as DPPC. Unsaturated
acyl chains impose a steric hindrance that opposes highly lateral pack-
ing, strictly required to minimize surface tension during the compres-
sion of the alveolar interface (see Section 2.3).
However, spontaneous interfacial adsorption (transfer to the inter-
face, see Section 2.2) of phospholipids is an intrinsically slow process,
and desorption contributes to the loss of phospholipids from the inter-
face. To optimise these processes, surfactant complexes contain not
only phospholipids but also two small hydrophobic proteins (SP-B and
SP-C) that are stably associatedwith phospholipids. These proteins dra-
matically enhance interfacial adsorption of phospholipids and help to
maintain the interconnected surfactant structures.Fig. 2. Structural models of surfactant proteins and their interaction with surfactant phospholip
SP-B dimer, the resolved structure in organic solvent of SP-C [52], and a structural model of a d
leaﬂets).1.1.2. Surfactant proteins
There are four surfactant proteins known to directly participate in
pulmonary surfactant-associated functions. Their model structures
and their organisation at the alveolar spaces are presented in Fig. 2.
SP-A, SP-B and SP-C are obtained from the airways associated with sur-
factant phospholipids and are therefore considered apolipoproteins,
while SP-D is not. SP-D could still interact with phospholipids under
speciﬁc conditions, in surfactant or in other cellmembranes, because in-
teractions between SP-D and certain phospholipid species, such as gly-
colipids or PI, and fatty acids have been reported [36–39]. The small
hydrophobic SP-B and SP-C proteins participate in surface activity of
surfactant, while SP-A and SP-D play a major role in innate immune
defence.1.1.2.1. SP-B and SP-C. SP-B is a small protein with an elevated propor-
tion of hydrophobic amino acids (approximately 40%) that adopts a
mainlyα-helical secondary structure (30–45%) and has a 8.7 kDamolec-
ular mass [19,40,41]. SP-B belongs to the saposine-like family of proteins,
all of them containing 6 cysteines in strictly conserved positions that es-
tablish 3 intramolecular disulphide bonds [42]. In addition, SP-B has a
seventh cysteine that participates in an intermolecular disulphide bond
to form a covalent homodimer. SP-B has a net positive charge that en-
hances its interaction with anionic phospholipids, such as PG [29]. The
protein is orientated parallel to the membrane surface, establishing hy-
drophobic interactions between the amphipathic helical segments and
the membrane surface (Fig. 2) [43]. This superﬁcial disposition seems to
be very important for the protein to promote the interconnection of
membranes [44] through supradimeric oligomerisation of the protein
[42,45]. Moreover, SP-B induces permeability and aggregation of phos-
pholipid membranes [46–50]. These two processes could be essential
for surface activity of surfactant, particularly regarding the ability of the
protein to enhance interfacial adsorption of phospholipids. Through the
connections between membranes, SP-B might facilitate reﬁnement of
the interfacial ﬁlm during compression and the efﬁcient re-extension of
the material from the reservoirs during expansion (see Section 2.3). In
addition, these interconnected membranes may form a continuous net-
work that might be highly conductive for hydrophobic molecules, such
as oxygen, facilitating oxygen diffusion through the lung epithelium [51].id layers. Schematized are a structural model of octadecameric SP-A, a structural model of
odecameric SP-D (modiﬁed from [149]) in lipid layers (grey bands represent monolayer/
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ily α-helical secondary structure. The N-terminal segment of SP-C has a
positive net charge without a deﬁned secondary structure and includes
two palmitoylated cysteine residues; the C–terminal region is enriched
in branched aliphatic residues, such as valine, forming a highly hydro-
phobic α-helix [52]. This helix has a transmembrane orientation and a
~70° tilt relative to the plane of themembrane [53]. Both palmitic chains
play an essential role, anchoring the N-terminal segment to the mem-
brane (Fig. 2). Consequently, non-palmitoylated versions of the protein
are excluded from the interface more easily during compression of the
interfacial ﬁlm than the acylated forms [54,55]. The positive net charge
of SP-C allows it to establish preferential interactionswith anionic phos-
pholipids [29], and the protein seems to exhibit a special behaviour in
the presence of cholesterol. SP-C has an apparent protective role for sur-
factant in the presence of cholesterol, an activity that requires
palmitoylation of the protein [56,57]. Such effect could indicate that a
speciﬁc SP-C/cholesterol interaction could exist, involving the
palmitoylated segment of the protein; however, this feature has not
been proven.
1.1.2.2. SP-A and SP-D. These hydrophilic proteins are components of the
innate immune defence system, in charge of modulating the inﬂamma-
tory response while removing pathogens from the epithelial surfaces
[58]. SP-A and SP-D belong to the collectin family of proteins [59].
These proteins are responsible for recognising and opsonising micro-
organisms, presenting them to immune cells, such as alveolar macro-
phages, to enhance microbial clearance [60]. They also present
intrinsic antimicrobial activity in the absence of immune cells [61]. SP-A
and SP-Dbindnumerous types ofmicroorganisms, including viruses, bac-
teria, and fungi. SP-A binds lipopolysaccharides preferentially from
Gram-negative bacteria, while SP-D binds also to peptidoglycans and
lipoteichoic acid [62]. The structure of these proteins is optimised for
their function. They have globular domains able to recognise and bind
carbohydrates (CRDs, carbohydrate recognition domains) at the patho-
gen surface. Moreover, SP-A can bind DPPC through these domains [63].
The interaction between SP-A and the phospholipids via the CDR domain
might be critical to the formation of tubular myelin [58], which is a regu-
lar network of membranes extended by the surfactant at the airways. In
addition, by binding to phospholipids through this domain, it also partic-
ipates in recycling and clearance of surfactant by type II cells and macro-
phages. As a matter of fact, SP-D is essential for regulating the pool of
surfactant and surfactant homeostasis [64]. The neck and collagen do-
mains of these collectins are critical for stabilising their oligomeric
forms. Finally, the N-terminal sequences seem to be critical not only for
stabilisation of oligomers but also for interaction with phospholipids
and the formation of tubular myelin [65].
1.1.3. Surfactant membrane structure
1.1.3.1. Lipid phases/membrane domains. As described above, pulmonary
surfactant phospholipid composition has evolved to contain approxi-
mately 50% saturated and 50% unsaturated species; special remodelling
pathways in pneumocytes provide this unusual molecular composition
relative to the typical phospholipid composition in any other cell mem-
brane [66]. The coexistence of saturated and unsaturated phospholipids
in surfactant responds to the simultaneous requirement of a high stabil-
ity for surfactant layers at high compression rates, particularly well
sustained by saturated molecules, such as DPPC, and enough ﬂuidity
and dynamics, which are facilitated by unsaturated species to permit
structural transformations associated with the transference of surface
active molecules from cells to the air–liquid interface.
When assembled in bilayers, phospholipids undergo a thermotropic
transition between an ordered state at low temperature, typically called
the gel (Lα) phase, and amuchmore disordered state at higher temper-
atures, the liquid-crystalline (Lα) phase. In the gel phase,molecules have
little rotational or translational mobility and adopt a quasi-crystallineorder with homogeneous well-deﬁned intermolecular distances and
extensive packing of their acyl chains. At temperatures above a certain
threshold, the melting temperature, or Tm, phospholipid bilayers tran-
sition from the gel phase to a liquid-crystalline phase, gaining consider-
able mobility and losing their short-range organisation as well as
exhibiting a high number of gauche conﬁgurations at the C\C bonds
of the acyl chains. The Tm of a given phospholipid depends on the num-
ber of double bonds and length of its acyl chains,with long, fully saturat-
ed chains undergoing ordered-to-disordered transitions atmuch higher
temperatures than shorter or unsaturated chains. Bilayersmade of pure
DPPC, themain surface active species in surfactant,melt fromordered to
disordered phase at 41 °C, while POPC, one of themost abundant unsat-
urated species, melts at−2 °C. Consequently, membranes made of sur-
factant phospholipids exhibit a coexistence of ordered and disordered
phases at a wide range of temperatures, including physiological values
[45,67,68]. However, cholesterol modulates the organisation and dy-
namics of these phases. The rigid sterol molecules intercalate between
phospholipid molecules, enhancing molecular mobility below Tm and
restricting the extent of the disorder by limiting the number of gauche
conformers of the acyl chains above themelting temperature. Therefore,
below the Tm, cholesterol converts the gel phase into a so-called liquid-
ordered (Lo) phase, which is ordered but ﬂuid due to the considerable
mobility gained by individual molecules. This Lo phase transforms into
a liquid-disordered (Ld) phase at temperatures above the Tm. Recent
studies have conﬁrmed that pulmonary surfactant membranes exhibit
a coexistence of ordered and disordered ﬂuid phases at various temper-
atures (see Fig. 3). The lateral structure of surfactant membranes, as re-
vealed by confocal ﬂuorescence of giant liposomes [67,68] or by X-ray
scattering of non-labelled surfactant suspensions [45], consist of Ld do-
mains interspersed in a DPPC-enriched cholesterol-containing matrix
of Lo-like phase. Surfactant proteins SP-B and SP-C partition exclusively
into Ld domains, contributing to their highly dynamic character, fre-
quently associatedwith protrusions and deformations thatmay precede
three-dimensional structural re-organisations [68,69]. Removing cho-
lesterol from surfactant membranes converts the coexistence of ﬂuid
Lo/Ld phases into a complex lateral pattern presumably composed of a
solid gel-like ordered phase segregated from a disordered phase. The
mobility of lipids in surfactant membranes upon cholesterol removal
decreases strongly [67]; functional impact of this effect has not been
fully assessed, even though most clinical surfactant preparations are
fully depleted of cholesterol [70].
Once transferred into the air–liquid interface, lipid ﬁlms also organise
into ordered and disordered phases, depending on lipid composition,
temperature and compression state. If the interfacial ﬁlm contains
enough disaturated phospholipid and is compressed at a temperature
below its Tm, the area reduction promotes the formation of condensed
domains in which the individual phospholipids organise analogously to
the gel phase in bilayers with a high extent of packing and a quasi-
crystalline two-dimensional organisation. Domains of the so-called
liquid-condensed (Lc) phase are therefore formed during compression.
Atmaximal compression, a two-dimensional solidﬁlmmay form. Surfac-
tant interfacial ﬁlms with saturated and unsaturated phospholipids seg-
regate upon compression Lc domains ﬂoating in a liquid-expanded (Le)
phase equivalent to the Lαphase of bilayers. If the interfacialﬁlm contains
cholesterol, the Lc/Le coexistence converts into a coexistence of Lo/Ld ﬂuid
phases. Films formed by the full lipid fraction of surfactant segregate
small round and presumably ﬂuid condensed domains during compres-
sion [71,72]. These domains are enriched in DPPC [73] but likely contain
other saturated phospholipids and cholesterol and are partially remixed
at high compression rates, a behaviour that depends on the presence of
cholesterol [74–76].
1.1.3.2. Lamellar and non-lamellar lipid phases. Surfactant lipid com-
plexes have been traditionally considered to act through the formation
of a single surface active monolayer at the interface. Later, it was pro-
posed that the interfacial monolayer is interconnected withmultilayered
Fig. 3. Phases and lateral structures in pulmonary surfactant membranes and ﬁlms. Pulmonary surfactant membranes exhibit coexistence of a DPPC-enriched cholesterol-containing
liquid-ordered phase (Lo) and a liquid-disordered (Ld) phase in which surfactant proteins SP-B and SP-C selectively partition. Represented is an interpretative cartoon and a picture of
a ﬂuorescently labelled giant unilamellar vesicle (GUV) made of pulmonary surfactant (red, diIC18; green, BODIPY-PC; diameter of the GUV, 20 μm). Interfacial ﬁlms of surfactant
have been shown to segregate under compression excluding DPPC-enriched ordered domains from a ﬂuorescent (NBD-PC labelled) liquid-expanded (Le) phase. Shown are an explicative
cartoon and an epiﬂuorescence picture (scale bar is 100 μm). Proteins SP-B and SP-C are presented as selectively interacting with disordered phases, both in bilayers and monolayers.
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ing as reservoirs for interfacial phospholipids are interconnected through
the surfactant proteins, even forming porous structures [77] or non-
lamellar phases [78]. These interconnections could be important for facil-
itating rapid diffusion of surface active lipid species toward the interface.
Porous structures also facilitate rapid diffusion of polar molecules (ions,
defence proteins and peptides) through surfactant membranes [47,48],
leading to the question of whether surfactant actually assembles a sort
of bicontinuous phase that could facilitate a rapid and efﬁcient diffusion
of both polar and non-polar molecules along the entire liquid layer lining
the respiratory epithelium [13]. The interconnected pored bilayers could
contain truly non-lamellar phases, the existence of which remains to be
fully explored. In this sense, it is remarkable that lipids that facilitate
the formation of inverted hexagonal HII phase promote surface activity
[79] and that surfactant proteins SP-B and SP-C promote the formation
of cubic phases in model lipid/protein systems [78,80,81]. The increasing
evidence of porous structure formation by surfactant proteins lead us to
believe that protein–lipid complexes of surfactant are far more complex
than expected and that these poring structures may play an important
role regarding surfactant function and oxygen diffusion [51].
1.1.4. Surfactant biology
During embryonic development, the lungs are the last organs to
develop. At week 35 of gestation, the lungs are ready to breathe,
and alveolar epithelial type II (ATII) cells have already synthesised
surfactant. The lung epithelium is mainly composed of two epithelial
cells, type I (ATI) and ATII. ATI cells are large cells, covering approx-
imately 90% of the alveolar surface. The basal membrane of these
cells is in close contact with endothelial cells from the capillary;
therefore, through the ATI cell, gas exchange occurs from alveolarspaces to the lumen of capillaries. ATII cells are in charge of synthe-
sising, secreting and recycling lung surfactant [82–84], making up
60% of alveolar epithelial cells. Both lipids and surfactant proteins
(SP-A, B and C) are synthesised and processed in these cells.
The ATII cells are enriched in endoplasmic reticulum (ER), where
surfactant lipids and proteins are synthesised [85]. Later, assembly of
lipids and proteins results in a tightly packed structure that is stored
in lamellar bodies, which are organelles that ultimately secrete surfac-
tant into the alveolar spaces [86]. Once secreted, surfactant maintains
a highly packed state [87,88] that partially reorganises to adopt a highly
organised network known as tubularmyelin [89]. Finally, phospholipids
are transferred with assistance from hydrophobic proteins to occupy
the entire alveolar air–liquid interface. At the interface, a phospholipid
monolayer enriched in DPPC is interconnected with the rest of surfac-
tant complexes that serve as reservoir (multilayers and multilamellar
arrays) in the subphase. Hydrophobic surfactant proteins might medi-
ate these interconnections, enhancing mechanical stability of lung sur-
factant at the interface [77].
The synthesis and transport mechanisms of surfactant lipids from
the endoplasmic reticulum to lamellar bodies are not entirely under-
stood. Themajor phospholipid in surfactant, PC, seems to be synthesised
by the CDP:choline pathway that includes CTP:cholinephosphate
cytidylyltransferase and cholinephosphotransferase [90]. Considering
that vesicle-mediated transport plays a key role in the processing of hy-
drophobic surfactant proteins, this pathway may be common to lipid
transport. SP-B and SP-C are also synthesised in the endoplasmic retic-
ulum, reaching multivesicular bodies (MVB) through the Golgi appara-
tus. Before entering lamellar bodies (LB), they are transferred through
different endosomal compartments as composite bodies (CB) [86].
However, the most recent hypothesis involving the surfactant speciﬁc
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transferred from the ER to LB through a vesicle independent mecha-
nism. This hypothesis is supported by localisation of ABCA3 at the limit-
ing membrane of LB [91]. Phospholipid transport between membranes
that remains independent of vesicles would be mediated by transport
proteins and lipid diffusion within contact points betweenmembranes.
The latter mechanism requires participation of proteins that should be
able to establish temporary contact with LB [66]. The ABCA3 phospho-
lipid transporter appears to be essential because its absence leads to
mortality, similar to the absence of SP-B [92,93]. ABCA3 belongs to the
family of ABC transporters, which bind and hydrolyse ATP coupled to
the transport of different molecules, such as phospholipids, through
membranes. ABCA3 is exclusively found in ATII cells, and its expression
is regulated by corticoids, being up-regulated immediately before birth
[82,84,94].
The processing and maturation of hydrophobic surfactant proteins
is coupled to synthesis and assembly of surfactant phospholipids. Both
SP-B and SP-C are proteins synthesised as large precursors that suffer
multiple proteolytic cleavage steps before reaching their mature forms
(Fig. 4). The two proteins follow a parallel pathway of endosomal pro-
cessing from the ER to the LB, possibly sharing processing enzymes. Al-
though it has not been directly established, several evidences seem to
indicate a coordinated processingmechanism for both proteins. The ab-
sence of SP-B alters processing and sorting of SP-C, reﬂecting this con-
nection between processing and trafﬁcking of both proteins in ATII
cells [95]. In addition, genes from both proteins are regulated by the
same transcription factor: TTF-1 (thyroid transcription factor 1). TTF-1
is a phosphorylated nuclear transcription factor that is essential for dif-
ferentiating the lung epithelium during development. TTF-1 binds nu-
merous factors that regulate transcription of genes, including those
coding for surfactant proteins SP-A, SP-B and SP-C (SFTPA, SFTPB and
SFTPC) [96]. TTF-1 deletion is lethal in animal models, and differential
phosphorylation states allow researchers to study its involvement
in lung and surfactant development [97]. Fig. 4 summarises the proteo-
lytic cleavages and intracellular compartments involved in processing of
SP-B and SP-C [98–103]. Both proteins are synthesised as much larger
precursors (proSP-B and proSP-C) with N- and C-ﬂanking domains. Al-
though little is known about the function of these propeptide segments,Fig. 4. Processing pathways of SP-B and SP-C in ATII cells. SP-B is synthesised as a 40–42 kDa
multivesicular bodies (MVB) through the Golgi. Two enzymes, Cathepsin H and Pepsinogen C s
posite bodies (CB) to LB [253]. On the other hand, SP-C is also synthesised in the ER as a 21 kDa
C-terminal domain and later, probably Cathepsin H cleaves the N-terminal domain resulting inthey may possess a chaperone function while forming part of the
precursor, facilitating proper folding of the protein and protecting
the highly hydrophobic mature domains from exposure to the
polar cellular environment. The C-terminal domain from proSP-C
contains a BRICHOS structural domain [104] and has been related
to the proper folding of the precursor protein [101]. On the other
hand, the N-terminal and C-terminal propeptides of proSP-B contains
saposin-like domains and may perform an antibacterial function due
to their similarity to proteins with citolytic and antibacterial properties,
such as amebapores, granulysin or NK lysine [42,105].
2. Surfactant activity
2.1. Surface tension
Surface tension (γ) of a liquid is the energy needed to increase its
surface in a unit of area and is therefore expressed in energy per unit
of area or length (J/m2 or mN/m). Therefore, γ quantiﬁes the energy
needed to overcome the forces that minimise the area exposed to ame-
dium other than the liquid. Surface tension is generated by the attrac-
tive forces between liquid molecules. Inside the liquid bulk phase,
attractive forces act in all directions and are compensated for between
molecules. However, at the interface, these attractive forces are not
fully compensated, producing a net attractive force toward the interior
of the liquid. For the lung epithelium, which is covered by a thin layer
ofwater, these forces play an important role inmechanical and structur-
al stabilisation of the lungs during the breathing process. If these forces
are not minimised during exhalation, the smallest alveoli would be
prone to collapse because surface tension would minimise the area ex-
posed to the air, reducing the area available for gas exchange [106,107].
Evolution has developed a surfactant that minimises these surface
forces, particularly phospholipid components placed at the interface,
displacing water molecules away from the interface to compensate for
the attractive forces and therefore reducing surface tension. When
the interface is fully occupied by phospholipid molecules, an equili-
brium surface tension (γeq) is reached. Adding more phospholipid
molecules does not further decrease surface tension because adsorption
to and desorption from the interface would compensate for one another,precursor that is cleaved by Napsin A. The resulting intermediate of 23–26 kDa reaches
eem to be involved in the ﬁnal processing of SP-B which takes place in intermediate com-
precursor that is palmitoylated in the Golgi apparatus [103]. Unknown enzymes cleave the
the mature protein at the LB [99]. Figure modiﬁed from [98,99,102,103,180].
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surface varies continuously while it is compressed during exhalation
and expanded during inhalation according to breathing cycles. To
avoid alveolar collapse, surfactant reduces surface tension below equi-
librium to aminimal value (γmin) during compression due to its speciﬁc
phospholipid composition, which is enriched in DPPC, allowing higher
packing of its disaturated acyl chains.
2.2. Adsorption at the interface
Pulmonary surfactant should show a fast interfacial adsorption
while equilibrating surface tension to stabilise the lungs. During this
process, the surfactant proteo-lipid complexes reach and spread
into the interface from the sub-phase, forming a surface active inter-
facial ﬁlm. The interfacial adsorption process includes both arrival and
accumulation of material near the interface, and the ultimate transfer
processes that insert the molecules into the interface, forming a layer
exposed to air (see Fig. 5). The interfacial adsorption of lipids is not en-
ergetically favourable because transfer of phospholipids implies a tran-
sient exposure of lipid acyl chains to the aqueous environment, making
the process slow and inefﬁcient. Hydrophobic proteins, such as SP-B and
SP-C, are essential for lowering the energetic barrier for transferringma-
terial to the interface, likely protecting and stabilising the intermediates
involved, making this process fast (on the scale of seconds). Surfactant
proteins would therefore act as true catalysts, reducing the energy re-
quired to reach the “transition state” during interfacial transfer. Typical-
ly, surfactant reduces the surface tension from approximately 70mN/m
(the surface tension of the aqueous sub-phase) to 22–23 mN/m, which
is the equilibrium surface tension of surfactant, in 2–3 s. This is essential
to allow the opening andmechanical stabilisation of the lungs of a new-
born baby.
2.3. Compression–expansion of the interfacial ﬁlm
Surfactant interfacial ﬁlms are constantly subjected to compression
and expansion of the alveolar surface. To stabilise open alveoli, surfac-
tant should maintain a low surface tension during successive breathing
cycles. Therefore, surfactant should pack the interfacial ﬁlm efﬁciently
during compression, re-extending and re-adsorbing the interfacial ﬁlm
during expansion (Fig. 6).
During exhalation, the lungs lose approximately 10% of their volume,
mainly translated into volume changes in the upper airways. Surfactant
reduces surface tension according to the alveolar size (Laplace Law), so
that volume changes are minimized at alveolar airspaces [108]. Toward
this purpose, the interfacial ﬁlm is laterally compacted; this process is
optimised due to the presence of enough disaturated phospholipids,Fig. 5. Steps in interfacial adsorption of pulmonary surfactant. Adsorption of pulmonary surfac
andmassivemovement of largemultilamellar arrays close to the interface compartment, 2) atta
protein–lipid and protein–protein interactions, and 3) Ultimate transfer of surface active lipidm
tures in which surfactant proteins SP-B and SP-C likely participate.such asDPPC, which is able to sustain very tight packing of their saturat-
ed acyl chains. During compression, the interfacial ﬁlm is thought to be
further enriched inDPPCdue to the exclusion of an important fraction of
unsaturated phospholipids and neutral lipids to multi-layered com-
plexes and the reservoir at the sub-phase; this process has been called
the “squeeze-out” process [109]. The lower stability of the ﬁlm regions
that are rich in unsaturated species would facilitate this depuration
once the highest lateral pressures are reached. This processmay be facil-
itated by formation of pore-like structures or fusion/adsorption inter-
mediates, enhancing exclusion of unsaturated phospholipids from the
interfacial ﬁlm [77]. The hydrophobic SP-B and SP-C proteins would
take part of these structures because they are essential for minimising
surface tension during compression [45,110].
Similarly, an efﬁcient re-extension of the interfacial ﬁlm upon expan-
sion would be essential for maintaining equilibrium surface tension
(22–23 mN/m) during inhalation. This re-adsorption process involves
transfer of protein–lipid complexes from the interconnected material at
the reservoirs back into the interface. This process is also enhanced by
hydrophobic proteins, most likely through the same fusion/adsorption
connecting structures already formed during compression [77] and is im-
portant for minimising the energy required to expand the alveolar inter-
face and stabilise the lung epithelium. Good operative surfactant ﬁlms
exhibit reduced or no hysteresis and very limited area compression
(b20%) while reaching minimum surface tension (2–3 mN/m).3. Surfactant inactivation
Low surface tension contributes to alveolar stability according to
Laplace's Law. Laplace's equation (ΔP= 2γ/R, where P is closing pressure
of an ideal spherical chamber, γ is surface tension and R is radius) estab-
lishes that two interconnected alveoli with different radii and same sur-
face tension cannot coexist at a given pressure. The pressure in the
smaller alveoluswould cause it to collapse into the larger one. By variably
decreasing surface tension as a function of alveolar size, surfactant plays a
major role in stabilising the lungs [111]. Accordingly, loss of surface activ-
ity leading to increased alveolar surface tension is assumed to cause
alveolar instability and atelectasis. Therefore, increasing surface tension
may result in a marked decrease in lung compliance [112].
Surfactant inactivation refers to all processes that interfere with and
decrease surface activity of surfactant. Because surface activity of surfac-
tant is essential for breathing, surfactant inactivation is life-threatening.
To date, surfactant inactivation has been tied to various respiratory dis-
eases with different origins and outcomes. Surfactant inactivation may
not be the reason for nor the consequence of the impaired lung function
associated with respiratory diseases, but an increasing body of evidencetant to form surface active ﬁlms at the air–water interface includes 3 main steps: 1) rapid
chment and association of surfactantmembranes to pre-existingﬁlms, likely promoted by
olecules into the air-exposedmonolayer, possibly through non-bilayer intermediate struc-
Fig. 6. Surfactant interfacial ﬁlms during compression and expansion of the interface. Left: compression of the interfacial ﬁlm produces a selective exclusion of mainly unsaturated phos-
pholipids and cholesterol out of themonolayer to the interconnected reservoir by a process known as “squeeze-out”. Right: expansion of the interfacewith re-adsorption ofmaterial from
the reservoir into the interfacial monolayer. Both processes are facilitated by hydrophobic surfactant proteins [66].
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and outcome of these diseases [17,112–120].
A summary of the molecular mechanisms and sources of surfactant
inactivation is presented in Fig. 7. Surfactant inactivation may be
caused by exogenous agents, including inactivating agents that are not
normally present in alveolar spaces but interfere with the surfactant
after reaching the alveolar interface. This phenomenon occurs when
surface-active components from serum reach the interface through a
leaky epithelial–vascular membrane, as in the case of lung injury. Alter-
natively, direct aspiration would introduce external agents directly into
alveolar spaces, making contact with surfactant complexes. For exam-
ple, aspiration of meconium occurs in 2% of deliveries when meconium
stains the amniotic liquid. Meconium is then mixed with surfactant at
the interface, rendering it dysfunctional. Membrane-perturbing mole-
cules, such as cholesterol, may perturb surfactant membrane properties
and convert them into non-functional structures. However, the origin of
surfactant inactivation can also be endogenous; ATII cells that are in
charge of synthesis, assembly and storage of surfactant complexes
may function abnormally. Whether there is a genetic disorder associated
withmutations at genes related to surfactant, particularly those essential
for surfactant function (such as SFTPB, SFTPC,ABCA3, orNKX2.1), or an im-
pairment of surfactant metabolism by ATII cells, the result changes sur-
factant composition.3.1. Exogenous inactivation
Exogenous inactivation may occur when inactivating substances
reach alveolar spaces. Inactivating substancesmay arise from inﬂamma-
tion, leakage from vascular spaces and direct aspiration. Inﬂammation
processes directly associated with lung injury serve as a mechanism
for surfactant inactivation: 1) by damaging the available alveolar surfac-
tant due to the liberation of proteases, lipases and/or free radicals; 2) by
damagingATII cells required for new surfactant synthesis, recycling, and
release; and 3) by damaging the alveolar–capillary permeability barrier,
leading to leakage of inactivating agents from the serum into theFig. 7. Scheme of the different sources and molecular mechanisms of inactivation of surfactant
(when inactivating substances reach the alveolar spaces) or endogenousmechanisms (abnorma
the purple boxes.alveolar surface andair–liquid interface [121]. In addition, direct aspiration
of exogenous substances may also impair surfactant function due to the
action of inactivating agents on surfactant surface activity or membrane
structure. Traditionally, two major molecular mechanisms are invoked
for surfactant exogenous inactivation: i) those that are primarily related
to surface-active molecules that compete with surfactant for the interface
and ii) those originated by membrane-perturbing molecules that insert
into and disrupt the structure of surfactant [34].3.1.1. Surface-active molecules
Under pathological conditions, surfactant may encounter other
surface-active molecules competing to reach and stably associate with
the interface [122–125]. For example, albumin is one of the most abun-
dant proteins in serum and is a surface-active protein that is able to re-
duce surface tension down to equilibrium values of 45–50 mN/m
[126–128]. For albumin, similar to the case of detergents, compressing
the interface does not decrease surface tension further. Thesemolecules
establish an equilibrium in which albumin molecules are adsorbed and
desorbed to and from the interface during compression. As shown in
Fig. 8, under normal conditions, surfactant can reach the interface with-
in a few seconds, but if the interface is already occupied by an excess of
other surface-active molecules, surfactant complexes cannot overcome
the steric and electrostatic barrier imposed by proteins at the interface
and do not form the highly surface-active ﬁlm [123–125]. Therefore,
in the presence of serumor albumin, the interfacial adsorption of surfac-
tant is impaired, generating an abnormally high surface tension
[125,129,130].
Acute Respiratory Distress Syndrome (ARDS) is a respiratory pathol-
ogy where surface-active molecules reach the interface. ARDS is
characterised by respiratory failure with many different origins, always
related with severe lung inﬂammation [131]. The mortality associated
with this syndrome is 36–44% [132]. Due to inﬂammation in the lung,
the underlying alveolar and vascular injury leads to impaired vascular
permeability, causing leakage of serum and plasmatic proteins from
the blood capillaries into alveolar spaces. In addition to albumin, otherunder pathological conditions. Sources of inactivation (in blue) include exogenous agents
l function of ATII cells); potentialmolecularmechanisms of inactivation are summarized in
Fig. 8. Inactivation of surfactant complexes through competition for the interfacewith surface-activemolecules. Under normal conditions, surfactant adsorption at the interface is very fast, but
under pathological conditions when surface-active molecules reach the interface, surfactant is not able to overcome the steric barrier and does not reach the interface. Modiﬁed from [34].
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agents against surfactant [133–135]. The presence of surfactant producing
abnormally high surface tension has already been described in patients
suffering from this disease [136–139]. If the alteration in surfactant activ-
ity somehow contributes to development and outcome of ARDS, surfac-
tant replacement therapy (SRT) should mitigate the effects of such
abnormally high surface tensions [140]. To date, clinical trials have dem-
onstrated some beneﬁcial effects of SRT but have failed to improve
patients' survival [141–143]. The problem is that clinical surfactants ap-
plied during SRT may undergo the same inactivating processes affecting
endogenous surfactant, resulting in impaired function. Therefore,
development of improved inactivation-resistant clinical surfactants is a
crucial step.
However, it is probable that clinical research will have to solve two
major problems before SRT would be a good option to ameliorate
ARDS. A ﬁrst problem is the poorly deﬁned nature of ARDS itself, which
makes the group of ARDS patients too heterogenous. Usually it includes
both patients in which an impaired surfactant and an abnormally high
surface tension is part of pathogenesis and patients in which surfactant
deﬁciency might be a consequence rather than a cause of the pathology.
The suitability of these two different types of patients for SRT could be
very different, aswell as the potential outcomederived from it. The deter-
mination and monitoring of a set of proper functional parameters could
aid to better deﬁne the group of ARDS patients associatedwith a primary
deﬁciency of surfactant function, which could be the best candidates to
receive SRT [144]. On the other hand, an early intervention to treat pa-
tients at risk of severe ARDS might be crucial to have a positive output
upon SRT application. Usually, the need for intubation to administer exo-
genous surfactant prevents approaching early treatments at the primary
stages of the pathology. In this sense, the development of new SRT strat-
egies, such as efﬁcient administration of aerosolized surfactants
(see below), could opennewwindows to earlier andmore effective treat-
ments, before an extensive surfactant inactivating environmentwould be
established in a fully inﬂamed lung. A second important strategy will be
probably the deﬁnition of good molecular markers that could allow an
early detection of primary states of surfactant dysfunction and defective
pulmonary mechanics. This will also contribute to make possible early
SRT, which could restore surfactant activity before an intrinsically unsta-
ble respiratory surface will ﬁnally end in irreversibly damaged lungs.
3.1.2. Membrane-perturbing molecules
Under pathological conditions, surfactant complexesmay also incor-
porate spurious components from substances reaching alveolar air-
spaces, such as cholesterol or free fatty acids from serum. In another
example, exposure to meconium that occurs during meconium aspira-
tion syndrome (MAS), results in incorporation of cholesterol into sur-
factant membranes and ﬁlms [145]. Cholesterol is one of the most
studied molecules with respect to membrane and surfactant structure
and function [67,68,130,133]. Cholesterol content in surfactant
appears to be governed by numerous factors, including diet or bodytemperature, and small changes in surfactant cholesterol content are as-
sociated with modulated surfactant activity [146–148]. This effect is
likely related to the ability of cholesterol to modulate biophysical prop-
erties, organisation and distribution of segregating lipid phases in sur-
factant membranes and interfacial ﬁlms [67,68]. As discussed above,
cholesterol is responsible for liquefying the Lβ phases, while it con-
denses the liquid-crystal Lα phases. Incorporating enough cholesterol
into surfactant membranes converts these phases into liquid-ordered
Lo state, where phospholipids may retain ordered states, with
high packing and low hydration, as occurs in Lβ ordered phases, but as-
sociated with signiﬁcantly higher lateral and rotational mobility
[33,149–151].
The structural perturbation of lipid phases in surfactant membranes
modiﬁes their biophysical activity. Excess cholesterol generates exces-
sively ﬂuid membranes, leading to early collapse of the interfacial
ﬁlms (illustrated in the cartoons of Fig. 9); therefore, low surface tension
is not reached under compression–expansion conditions [130,152,153].
In this case, there is no steric barrier against interfacial adsorption, and
surfactant complexes rapidly form an interfacial ﬁlm that lowers surface
tension, reaching values near equilibrium surface tension. However,
impairing surfactant function during compression–expansion may
lead to alveolar collapse and atelectasis, similar tomeconium aspiration
syndrome [115]. High cholesterol content in surfactant has been related
to respiratory diseases, such as MAS [115,145,154], ARDS [133], ventila-
tion induced lung injury (VILI) [155] and idiopathic pulmonary ﬁbrosis
(IPF) [156]. All of these alterations have very different origins, yet end
with an abnormally high proportion of cholesterol associated with sur-
factant complexes and associated impairment of surfactant function.
Several studies have suggested that the tight modulation of cholesterol
levels in surfactant membranes may be one of physiological mecha-
nisms that alters surfactant to ﬁt speciﬁc environmental demands,
such as strenuous exercise, variable respiratory rates or changing body
temperatures [146–148,157,158]. Therefore, exacerbated proportions
of cholesterol in surfactant could be a consequence rather than a
cause of the impaired respiratory function associated with pathology
because incorporating cholesterol into surfactant might be part of the
physiological response attempting to ameliorate dysfunctional respira-
tory mechanics.
Finally, not only can cholesterol interfere with biophysical activity of
surfactant but so can othermolecules thatmodify surfactant membrane
and interfacial ﬁlm structures, such as free fatty acids [133,134],
lysophospholipids [159–161], or C-Reactive Protein (CRP) [135,162].
3.2. Endogenous inactivation
Abnormal ATII cell function regarding synthesis, assembly and secre-
tion of surfactant is the origin of many lung disorders. Genetic disorders
resulting in surfactant protein deﬁciency are a known origin of lung dis-
ease in neonates. Mutations in genes encoding for proteins essential for
surfactant biophysical activity have fatal or chronic outcomes. In
Fig. 9. Inactivation of surfactant by membrane perturbing molecules. Under normal conditions phase segregation of surfactant phospholipids is supposed to maintain the proper ﬂuidity
along the compression–expansion cycling. Ordered domains (enriched in DPPC) are represented in a dark purple colourwhile disordered domains are represented by light purple. Under
pathological conditions, when a membrane-perturbing molecule is present, changes in phase segregation as well as an increase in ﬂuidity render surfactant dysfunctional.
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or an accumulation of the precursors and mature proteins have also
been related to chronic disorders. Moreover, modiﬁcations in surfactant
lipid composition caused by changes in surfactant metabolism may af-
fect lateral structure and compressibility of membranes and interfacial
ﬁlms as well as surfactant surface activity. ARDS or IPF (Idiopathic
Pulmonary Fibrosis) patients show signiﬁcant alterations in their sur-
factant lipid compositions, impairing surfactant structure and surface
activity [16,17,116].
3.2.1. Genetic disorders
Table 1 summarises the most important surfactant-related proteins,
their function and respiratory pathologies that are associated with their
deﬁciency or mutation. This reviewwill mainly discuss the involvement
in pathology of proteins relevant to surfactant surface activity, particu-
larly SP-B and SP-C. SP-A and SP-D have an immunomodulatory func-
tion; therefore, their absence is correlated with lung infections. ABCA3
and TTF-1 are proteins that remain uninvolved in surfactant surface ac-
tivity; rather, they participate in proper surfactant synthesis, secretion
and metabolism. Therefore, their abnormal function results in impaired
surfactant composition or storage within type II cells and will be
assessed in a subsequent section.
3.2.1.1. Deﬁciencies in SP-A and SP-D. Partial or total absence of SP-A and
SP-D is associated with impaired innate immunological defence func-
tions in the lungs and exacerbated inﬂammation rather than affecting
surface activity of surfactant. SP-A null mice show impaired clearance
of pathogenic microorganisms [22], such as group B Streptococci
[22,163,164], Haemophilus inﬂuenzae [64], Mycoplasma pulmonis [165],
Pseudomonas aeruginosa [166] and respiratory syncitial virus (RSV)
[164]. In addition, in the absence of SP-A no tubular myelin is observed
[65], linking SP-A with surfactant structure. However, because surfac-
tant biophysical function is not signiﬁcantly altered in SP-A- and tubular
myelin-deﬁcient animals, participation of tubular myelin in defence,
rather than remaining an intermediate during conversion of secreted la-
mellar bodies into the functional surface ﬁlm, becomes a possibility. SP-
D null mice are more susceptible to infection by RSV and IAV (Inﬂuenza
A virus). However these mice exhibit a rather complex phenotype, in-
cluding increased accumulation of lipids at airspaces, acute pulmonary
alveolar proteinosis (PAP) [167], foamy alveolar macrophages and
emphysema, contributing to development of chronic lung diseasesTable 1
Summary of surfactant-related proteins, their function and associated respiratory pathologies.
Protein Function Respiratory p
SP-A Pathogen binding and surfactant homeostasis [239] Lung infectio
SP-B Fast interfacial adsorption and interfacial ﬁlm stability [13,110,240] Neonatal resp
SP-C Interfacial ﬁlm stability [32,151,241] Chronic path
lung disease
SP-D Pathogen binding and surfactant homeostasis [64] Lung infectio
ABCA3 Lipid transporter, biogenesis of lamellar bodies [82,84,248,249] NRDS [92,93]
TTF-1 Transcription factor, development of the lung [96,250–252] ILD [190] and[24]. Although the mechanisms by which SP-D regulates surfactant
homeostasis remain unknown, it seems that SP-D could be involved in
the conversion to and the reuptake of small surfactant aggregates
[168,169].
3.2.1.2. Deﬁciencies in SP-B. Deﬁciencies in SP-B are lethal in babies
with mutated SFTPB gene [170]. These infants show symptoms of neo-
natal RDS (respiratory distress syndrome) because they lack a function-
al surfactant [143,171] but cannot be rescued by applying an exogenous
surfactant. Also SP-B knock-out mice die of severe RDS, typically within
minutes of birth [26,172]. Even partial SP-B deﬁciency perturbs the lung
function [173,174]. Genetic modiﬁcations of the SP-B gene causes SP-B
deﬁciency as well as interrupt SP-B processing pathway, possibly lead-
ing to SP-B deﬁciency and impaired lung function; this situation applies
to sporadic IPF, where SP-B deﬁciency is conﬁrmed by bronchoalveolar
lavage (BAL) frompatients and the accumulation of unprocessed SP-B in
the lung tissue [175,176].
Biophysical studies also reveal the essential role of SP-B during sur-
factant activity. Animal models with partial SP-B deﬁciency have an im-
paired surfactant with an equilibrium surface tension of approximately
50 mN/m and a minimal surface tension upon compression–expansion
cycling of approximately 20 mN/m [173]. A closer look at SP-B function
was accomplished through functional characterisation of lipid–protein
mixtures mimicking SP-B deﬁcient surfactant [110]. Surfactant lipids
alone are not efﬁciently adsorbed at the interface to form surface active
ﬁlms; SP-B is oneof themost important proteins involved in the transfer
of material to the interface. When SP-B is completely absent, surfactant
lipids show equilibrium surface tension above 30 mN/m and slow ad-
sorption kinetics during expansion [110]. SP-B also enhances the efﬁ-
ciency of the process by decreasing the required area reduction and
therefore the energy required to reach a low enough surface tension
during compression. However, the impaired adsorption during expan-
sion associated with inability to maintain equilibrium surface tension
suggests that lack of SP-B also is associatedwith interfacial ﬁlm instabil-
ity. In fact, the stability of the compressed surfactant ﬁlms, as tested in
the CBS, demonstrated the signiﬁcantly impaired ability of SP-B-
deﬁcient mixtures to maintain low surface tension in compressed
ﬁlms subjected to mechanical perturbations [110].
3.2.1.3. Deﬁciencies in SP-C.Mutations in the SFTPC gene are related to in-
terstitial lung diseases in neonates, children and adults. Althoughathology associated to deﬁciency or mutation
ns [22,163,164,167]
iratory distress syndrome (NRDS) [26,170,172]
ologies such as idiopathic pulmonary ﬁbrosis (IPF) [175,176,182] and interstitial
(ILD) [242–245]
ns [246,247], chronic obstruction pulmonary disease (COPD) [24] and emphysema [23]
and ILD [186]
development disorders in the lung [97,189]
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tiated, biophysical studies indicate that SP-C could have a subtle role in
modulating surfactant behaviour at the interface, helping to stabilise the
lungs over the long term.Mice with a complete SP-C deﬁciency have an
impaired surfactant that shows an equilibrium surface tension of ap-
proximately 35 mN/m and normal minimal surface tension upon com-
pression–expansion cycling of approximately 2–3 mN/m [177]. In
contrast, ablation of SP-C expression in another mice model ends in se-
vere chronic respiratory failure [178], indicating that SP-C activity may
be vulnerable to changes in the genetic background and environment,
as is the case for patients suffering from SP-C deﬁciency [25]. A closer
look at SP-C function was obtained using lipid–protein mixtures mim-
icking SP-C deﬁcient surfactant [110]. When SP-C is completely absent,
surfactant lipids show an equilibrium surface tension of approximately
25 mN/m with somehow slower adsorption kinetics during initial and
post-expansion adsorption [110]; no effect is observed in compres-
sion–expansion dynamics because the presence of SP-B enables surfac-
tant ﬁlms to reach minimal surface tensions.
In vivo, the cause of SP-C-related pathologies frequently relies more
on the accumulation of unprocessed proSP-C rather than the absence of
mature SP-C [25]. For example, the unprocessed forms of SP-C with an
extended N-terminus in neonatal RDS have impaired biophysical func-
tions [179]. Phospholipids in the presence of these aberrant forms can-
not lower surface tension during initial adsorption, producing
equilibrium surface tension above 50 mN/m. During repetitive com-
pression–expansion cycling, ﬁlms containing these proteins showed
an intermediate behaviour between phospholipids alone and phospho-
lipids with mature SP-C [179]. Moreover, the accumulation of aberrant
proSP-C forms within alveolar type II cells activates the unfolded pro-
tein response (UPR), possibly leading to ER stress and ATII cell injury.
Many studies have associated ILD in new-born babies with mutations
of SFTPC that lead to truncated or unprocessed proSP-C forms, following
the same cellular damage pattern as observed in conformational
disease-related proteins, such as Alzheimer's amyloid peptide or
Huntington's protein huntingtin [180]. Moreover, because SP-C seems
to counteract the deleterious effect of cholesterol on surfactant com-
plexes, the production and proper processing of an adequate amount
of this protein may also be important when surfactant is exposed to dif-
ferent inactivation agents, such as cholesterol. Speciﬁcally, proper
palmitoylation of the protein through the processing pathway may be
crucial for interaction with cholesterol or cholesterol-enriched mem-
branes in surfactant layers [56].
3.2.2. Impairment of surfactant metabolism
Not only does a deﬁciency inmature surfactant proteins cause respi-
ratory failure; it also occurs when there are interferences affecting pro-
cessing pathways, leading to a partial deﬁciency in mature proteins
and accumulation of unfolded precursors, generating similar outcomes.
Deﬁciency in proteases in charge of processing essential surfactant pro-
teins, such as SP-B, generates deﬁciency in themature biophysically ac-
tive protein. Decreased amounts of Napsin A (an aspartyl protease
involved in SP-B processing) have already been found in patients suffer-
ing from IPF [176]. NAPSA null mice show impaired SP-B processing and
express reduced amounts ofmature SP-C, leading to a pro-apoptotic ER-
stress signalling response [181]. Accumulating unfolded proteins in the
ER activates theunfoldedprotein response (UPR), activating the apoptotic
signalling pathways. For the ATII cells, these processes may cause type II
cell injury and consequently lung injury [182]. In general, a lung injury
of any origin affecting ATII cells alters normal cell metabolism, originates
the associated partial surfactant protein deﬁciency and changes in the
lipid proﬁle. An ultimate reduction in proper levels of surfactant proteins
B and Cmay lead to abnormal surfactant activity, generating high surface
tension. Subsequently, high surface tensionmay inducemechanical stress
in lung epithelium due to the repetitive alveolar collapse and forced re-
opening [183,184]. This mechanical stress can amplify alveolar cell
damage [183] and induce ﬁbrotic processes in the lung [185].3.2.2.1. Deﬁciencies in ABCA3. The relevance of ABCA3 was conﬁrmed by
inactivating the ABCA3 gene in mice. These mice were not able to open
their lungs after delivery and died shortly after birth [92]. Moreover,
lack of extracellular surfactant in these mouse lungs was associated
with lack of lamellar bodies in type II cells. Therefore, mutations in the
ABCA3 gene impaired surfactant production rather than altering its
function. Someof thesemutations in ABCA3 are thus relatedwith severe
surfactant deﬁciency [93] and are tied to ILD [186] in neonates.
3.2.2.2. Deﬁciencies in TTF-1. As stated before, TTF-1 is the transcriptional
factor that induces SP-A, SP-B and SP-C expression. Complete lack of
TTF-1 results in death due to impaired lung development [187], includ-
ing surfactant protein deﬁciency [188]. Moreover, a reduction in TTF-1
phosphorylation levels changes the regulation of cell differentiation
and causes a down-regulation of SP-A, SP-B and SP-C production. In
addition, Napsin A and CCSP (Clara cell secretory protein) expression
can be also impaired [97,189]. Although TTF-1 mutations are not com-
mon, some have been observed in patients with ILD [190] and have
been related to deﬁciency in surfactant proteins.
Changes in the phospholipid proﬁle of surfactant in patients suffer-
ing from ARDS or IPF reveal dysfunction of surfactant due to an altered
surfactant lipid composition. In this sense, lipid composition of surfac-
tant from the diseased lungs has been extensively studied. In general,
ARDS progress lowers the DPPC, PG and PC content, while PI, PE and
SM are increased. In addition, marked reductions in the SP-A, SP-B
and SP-C content have been detected. Associated with these composi-
tional alterations, ARDS patients show a reduced proportion of the
most surface active aggregates (large aggregates, LA) in surfactant; con-
currently, LA fraction contains an increased amount of neutral lipids. In
fact, increased amounts of cholesterol have also been reported in total
surfactant from ARDS patients [133]. As an additional factor, the
inﬂammation-induced increase in secreted phospholipases, such
as sPLA2, further alters the surfactant phospholipid proﬁle due to phos-
pholipid hydrolysis. Changes in surfactant activity have already been
correlated with sPLA2 activity in children suffering from ARDS [144].
Therefore, in ARDS, in addition to leakage of surface-active molecules
competing for the interface, changes in surfactant phospholipid pattern
generate an abnormally high surface tension. IPF patients also show al-
tered surfactant compositions, not only regarding the protein content,
such as decreased amounts of SP-B and SP-C in BAL, but also changes
in the lipid proﬁle, including a decrease in PG coupled with increased
PI and SM [16].
4. Surfactant therapy
Due to the complex aetiology of respiratory diseases, administering
a fully effective therapy remains a challenge. As stated in Section 3, dif-
ferentmolecularmechanisms of surfactant inactivationmay exist in dif-
ferent pathologies, and complex pathologies, such as ARDS or ILD, may
havemultiple inactivatingmechanisms simultaneously affecting surfac-
tant activity. Understanding molecular mechanisms behind surfactant
inactivation for different respiratory pathologies would help to develop
better surfactant preparations.
4.1. Surfactant replacement therapy
Surfactant is still considered to be an orphan drug by theWHO due
to the small number of patients requiring it. As stated before, surfac-
tant replacement therapy (SRT) SRT is prophylactically used in pre-
mature babies with or at risk for NRDS; no other use is currently
allowed. However, surfactant administration can offer several advan-
tages for patients with different respiratory diseases. The main
problem in the use of surfactant to treat various lung diseases, partic-
ularly those affecting adults who may need larger doses than neo-
nates, is its price and availability. Currently, natural surfactants from
animal sources are produced in a few countries at a high cost
1579E. Lopez-Rodriguez, J. Pérez-Gil / Biochimica et Biophysica Acta 1838 (2014) 1568–1585per dose. Several companies are attempting to develop new synthetic
surfactants based on simple mixtures of phospholipids and recombi-
nant human proteins or synthetic peptides — in principle, designed
to mimic functional motifs of the whole proteins. These synthetic sur-
factants avoid the risk of introducing materials from animal sources
into the human body. SP-B is essential for the biophysical function of
surfactant, and its absence is life-threatening. To the knowledge of
the authors, all attempts to produce recombinant versions of human
SP-B have failed. Alternatively, several initiatives have attempted to de-
velop second generation clinical surfactants by combining a lipid mixture
with an SP-B-mimicking peptide, such as KL4 [191] or mini-B [192,193].
KL4 is a very simple peptide that supposedly mimics the amphipathic
cationic nature of several helical segments of SP-B. Mini-B is a more elab-
orated SP-B-mimic, including segments from the SP-B N- and C-terminal
sequences, cross-linked by disulphides, such as the N- and C-terminal
ends of native SP-B [194]. While these peptides have shown some ability
to promote surfactant-like behaviour in vitro, they are still unable to re-
produce the full activity of native SP-B. However, recombinant human
SP-C has been produced in bacteria [194,195] with similar biophysical
and physiological properties as those imparted by native SP-C, at least
in the absence of cholesterol [56]. Synthetic surfactants containing recom-
binant versions of human SP-C have been developed and tested in clinical
trials. Unfortunately, the effectiveness of these entirely synthetic surfac-
tants against ARDS could not be demonstrated [140,142,195]. Surfactant
has proven to be useful in rescue of premature babies with healthy
but immature lungs and babies with damaged lungs who receive high
doses of clinical surfactant. The situation is very different in an adult
with severely damaged lungs, where multiple factors with different
origins converge to inactivate both the endogenous and exogenous sur-
factants. To date, several synthetic clinical surfactants have been devel-
oped, and most of them have been tested only in pre-clinical trials and
animal models of RDS: Venticute® (Nycomed, Germany) [195,196],
Surfaxin® (DiscoveryLabs, USA) [197] or CHF5633® (Chiesi, Italy) [198].
Surfactant therapy for adults with ARDS will only be possible after devel-
oping synthetic surfactants with enhanced inhibition resistance that can
be produced at a reasonable price.
4.2. Future perspectives
As stated, development of new surfactant preparations not only pur-
sues the production of synthetic preparations with a well-controlled
composition in large amounts at a reasonable price but also surfactants
with an enhanced resistance toward inactivation, improving its thera-
peutic efﬁciency during treatment of pathologies such as ARDS or
MAS. However, SRT still requires the patient to be intubated; this very
invasive procedure prevents surfactant administration in much earlier
stages of respiratory pathologies. The development of better clinical sur-
factant preparations will also include the exploration of alternative ap-
plication strategies, opening new opportunities for successful SRT
interventions in various lung diseases. Finally, new uses for surfactant
have been multiplying. Due to their optimal surface spreading proper-
ties, surfactants can be used as drug carriers that target the lung epithe-
lium. Most respiratory pathologies are likely too complex to be solved
by applying only surfactant. SRT in ARDS has not been successful in
decreasingmortality most likely because, in addition to surfactant inac-
tivation, there is also anoverwhelming inﬂammatory response associat-
ed with lung injury from very different origins. Similarly, one cannot
expect to treat on-going ﬁbrosis by only restoring low surface tension.
Combining a surfactant with anti-inﬂammatory, antibiotic or anti-
ﬁbrotic drugs may enhance the outcome of treatments for ARDS, ILD
or IPF patients.
4.2.1. Inactivation-resistant surfactants
Increasing the resistance of surfactant toward exogenous inactiva-
tion may lead to new surfactant preparations, generating improved
therapeutic strategies for treating ARDS or MAS; the current therapiesinvolving supplementation with exogenous surfactant are ineffective
because the exogenous surfactant becomes inactivated, similar to
the endogenous surfactant. Adding polymers, such as hyaluronan
(HA) or dextran, has proven to restore surfactant function in the
presence of some inactivating agents under speciﬁc experimental
conditions [123,199–202]. Moreover, these polymers have been tested
in vitro against various exogenous inactivating agents, probing their re-
storative capacity. Therefore, polymers may improve the performance of
surfactant complexes against various inhibitory agents through a com-
mon mechanism [129].
Adding polymers, such as HA, dextran or polyethylene glycol (PEG),
enhance the activity of surfactant in vitro and in vivo [203]. It has
been proposed that HA enhances surfactant adsorption through a steric
barrier due to the participation of depletion forces. This entropically
driven force pushes surfactant complexes toward each other, generat-
ing aggregated surfactant complexes, and toward the interface, enhanc-
ing adsorption [125] (see Fig. 10). Depletion forces have been used to
explain restored surfactant activity in the presence of competing
surface-active molecules at the interface. Due to these entropic forces,
surfactant may overcome the steric barrier imposed by surface active
proteins at the interface [124,203]. However, depletion forces do not ex-
plain why adding polymers to surfactant can also restore its activity
when inhibition is associated with incorporation of membrane‐
perturbing agents, such as cholesterol. Recently, we have described
that in addition to depletion forces, polymer-induced osmotic stress
may also induce a compositional reﬁnement, excluding cholesterol
and unsaturated phospholipids out of surfactant complexes [69] (Fig.
10). This process might mimic the compression-driven compositional
reﬁnement of surfactant interfacial ﬁlms, during the “squeeze-out” pro-
cess [21,109], enriching the mixture in saturated phospholipid species;
these species exhibit better surface tension lowering properties during
compression. This processmight therefore enhance resistance of surfac-
tant toward inactivation bymembrane-perturbingmolecules, revealing
a promising strategy for developing new surfactant preparations for
ARDS or MAS.4.2.2. Surfactant aerosolization/nebulisation
Currently approved SRT procedures involve the instillation of a
bolus containing a concentrated surfactant suspension directly into
the trachea, most commonly via an endotracheal tube, followed byme-
chanical ventilation. Intubation is an invasive procedure with some
risks, including oesophageal perforation, clinical instability associated
with accidental extubation and tracheal tube obstruction. Administra-
tion of intratracheal surfactant can be associatedwith apnoea, transient
hypoxia, bradycardia, hypotension and reduced cerebral blood ﬂow.
Therefore, a non-invasive approach for effective surfactant administra-
tion is desirable. Aerosolisation or nebulisation is a common process
used to deliver different drugs into the lungs. Several attempts have
been made regarding surfactant nebulisation in animal and human
models with interesting results [204–209]. Surfactant aerosolisation
for treating ARDS in animal models has generated variable outcomes
ranging from no change relative to the liquid suspensions to better sur-
vival rates in rats treatedwith aerosolised surfactants [210]. Even in ex-
perimental animal models, surfactant aerosolisation combined with
polymers, such as Dextran [211], improved the effect of surfactant,
prolonging the therapeutic response. Moreover, some pilot studies
with aerosolised synthetic surfactants [197], showed beneﬁcial effects
toward preventing RDS in neonates, offering a new strategy for surfac-
tant delivery into the lungs.
To reach distal airways, nebulised particles should be small [212].
Dispersing a concentrated lipid/protein suspension with the high vis-
cosity typical of clinical surfactants [213] is not trivial, and development
of nebulisers able to efﬁciently disperse nanodrops of exogenous surfac-
tant remains a technical challenge [214,215]. Evaluating the extent to
which the process of nebulisation/aerosolisation alters the structural
Fig. 10. Effect of polymers on surfactant structural and compositional properties. Depletion forces due to volume exclusion between surfactant complexes and polymers lead to aggregation
of surfactant, increasing its local concentration.Moreover, addition of a polymer creates a higher osmotic pressure outside surfactant complexes that are now under osmotic stress, releas-
ing itswater content. Osmotic shrinkage of surfactant vesicles leads to exclusion of highly disordered lipid domains (mainly containing unsaturated phospholipids and cholesterol) leading
to a reﬁning of composition similar to that occurring during the compression driven “squeeze-out”. On the left, the effect of depletion forces is illustrated on the aggregation state of sur-
factant [254], with addition of hyaluronan (HA) inducing aggregation of surfactant complexes. On the right, the effect of osmotic stress on surfactant composition [69], occurring upon
addition of HA to the subphase, and the consequent shrinkage and exclusion of unsaturated phospholipids and cholesterol.
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formance at the air–liquid interface is also critical [216].4.2.3. Pulmonary drug delivery
The spreading properties and inherent therapeutic potential of clin-
ical surfactants could be used to deliver drugs to the lung epithelium.
The direct delivery of drugs targeted to airways should increase their
local effectiveness while reducing their risk for systemic toxicity
[217,218]. In addition, lipid membranous structure of surfactant may
help solubilise hydrophobic drugs. For example, surfactant-like mix-
tures have been used as emulsiﬁers for lipophilic cancer drugs [219].
Mixing surfactant with an antibiotic (tobramycin) is more effective at
protecting mice from death due to respiratory Klebsiella pneumonia in-
fection than administering the antibiotic or surfactant alone [220].
The delivery of speciﬁc opsonising antibodies can also offer a new strat-
egy for ﬁghting infections. The incorporation of speciﬁc immunog-
lobulin against group B Streptococci (GBS) pneumonia into surfactant
reduced bacterial proliferation andwasmore effective than using either
the antibody or surfactant alone [221]. Given that the prophylactic ad-
ministration of surfactant may alleviate an asthma attack [222], it has
been speculated that adding bronchodilators to surfactantmay improve
their effectiveness [217]. In a rabbit model, using surfactant to
carry corticosteroids improved delivery signiﬁcantly with lower
systemic side-effects [223]. Moreover, a clinical trial has already dem-
onstrated that surfactant combined with budesonide (glucocorticoid
steroid) helps to prevent chronic lung diseases in preterm babies
[224]. Therefore, this strategy may be a promising tool for treating
lung injury-related diseases.
Genetic lung disorders, such as the ones discussed in Section 3.2.1,
cannot be treated with drugs because the genetic background is perma-
nently modiﬁed; the possibilities include only lung transplantation or
genetic therapy [225,226]. Different attempts have demonstrated that
adenoviral gene transfer of SP-A or SP-B cDNA [227,228] restores the ge-
netic deﬁciency of these proteins in vitro and in vivo, revealing a prom-
ising tool for treating inherited diseases. It is remarkable that the
combination of adenoviral vectors with surfactant enhances delivery
and distribution into the alveolar epithelium [229–231].Even thoughmany studies have demonstrated advantages of using a
surfactant as a drug carrier, little is known about the interactions be-
tween different drugs and surfactant complexes, either in the context
of the surfactant/drug complexes used as the carrier or with respect to
the endogenous surfactant that might impose a barrier, preventing the
drug from reaching the lung epithelium. For example, Gommers et al.
[232] analysed the incorporation of immunosuppressive drugs, such as
cyclosporine A (CsA) or rapamycin (RPM), into surfactant, ﬁnding
no apparent effects on the surface activity of surfactant with CsA and
impaired surface tension reduction with RPM. Therefore, studying the
biophysical and structural properties of surfactant/drug combinations
case by case is a major priority when attempting to understand and de-
velop surfactant-based strategies for delivering substances into the
lungs without interfering with the biophysical activity of endogenous
surfactant.
A recent and promising extension of surfactant use as a vehicle for
drug delivery is the combination of surfactant and different types of
engineered nanoparticles (NPs), potentially providing new and useful
properties, such as contrast imaging, hyperthermia generation or
targeted drug delivery. NP-based strategies are part of a huge emerging
ﬁeld in nanomedicine and deserve a speciﬁc chapter, with special atten-
tion to those involving NP/surfactant integration. Again, most of the
studies to date have attempted to analyse the impact of direct interac-
tion between surfactant and NPs on the tailored properties of these par-
ticles and on functional behaviour of surfactant [233–235]. Recentwork
has also analysed the effect of interactions of NPswith lung cells, such as
macrophages and ATII pneumocytes [236–238]. The pulmonary surfac-
tant layer at the respiratory surface is the ﬁrst system aspirated NPs
meet. Studying the interaction between surfactant and a catalogue of
available NPs is not only important when trying to develop new surfac-
tant/NPmaterials but alsowhen evaluating the potential impact of acci-
dentally inhaled NPs on surfactant function and, by extension, on
respiratory biophysics.
In summary, further research regarding the structure–function rela-
tionships in surfactant, particularly those focused on the role of different
components and structural organisations as well as the molecular
mechanisms associated with surfactant inhibition, will help to develop
better clinical surfactants, particularly for the challenging conditions
1581E. Lopez-Rodriguez, J. Pérez-Gil / Biochimica et Biophysica Acta 1838 (2014) 1568–1585imposed by an injured lung. The development of better clinical surfac-
tant preparations should also include the exploration of alternative ad-
ministration strategies, opening new opportunities for successful SRT
interventions in numerous lung diseases.
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